Stocknear Logo Stocknear
/
Popular
Login

Simulations Plus Inc.

32.66
0.46 (1.43%)
At close: Apr 17, 2025, 3:59 PM
32.69
0.11%
After-hours: Apr 17, 2025, 04:05 PM EDT
1.43%
Bid 30.18
Market Cap 656.12M
Revenue (ttm) 78.56M
Net Income (ttm) 7.22M
EPS (ttm) 0.36
PE Ratio (ttm) 90.71
Forward PE 26.2
Analyst Buy
Ask 34.62
Volume 295,789
Avg. Volume (20D) 259,032
Open 32.04
Previous Close 32.20
Day's Range 31.80 - 32.90
52-Week Range 23.01 - 51.22
Beta 1.13

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus...

[Read more]
Industry Medical - Healthcare Information Services
Sector Healthcare
IPO Date Jun 18, 1997
Employees 243
Stock Exchange NASDAQ
Ticker Symbol SLP
Website https://www.simulations-plus.com
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for SLP stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 53.12% from the latest price.

Stock Forecasts

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
6 days ago
+26.85%
Shares of healthcare technology stocks are trading... Unlock content with Pro Subscription
6 days ago
+0.74%
Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.
news image

1 day ago · seekingalpha.com

Simulations Plus: Benefiting From FDA Modernization And AI

Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, incl...

news image

6 days ago · benzinga.com

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

news image

1 week ago · seekingalpha.com

Simulations Plus: I See Promising Growth, But I'm Staying Neutral

Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and p...

news image

1 week ago · zacks.com

SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds

Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding.

news image

2 weeks ago · seekingalpha.com

Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript

Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & CO...

news image

2 weeks ago · zacks.com

Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates

Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.

news image

2 weeks ago · businesswire.com

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

news image

2 weeks ago · zacks.com

Simulations Plus Gears Up for Q2 Earnings: What's in the Offing?

SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints.

news image

4 weeks ago · businesswire.com

Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

news image

1 month ago · businesswire.com

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

Create Price Alert on SLP

Your price alert will notify you when the stock price is above 32.66.

Add to Watchlist